Omar Tliba

Dr. Omar Tliba

Department of Biomedical Sciences, College of Veterinary Medicine, Long Island University, Brookville, New York, NY, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
RPReynold A. Panettieri
Reynold A. Panettieri
DSDedmer Schaafsma
Dedmer Schaafsma
YAYassine Amrani
Yassine Amrani
CKCynthia Koziol-White
Cynthia Koziol-White
RORennolds Ostrom
Rennolds Ostrom
Omar TlibaOmar Tliba
Omar Tliba

Verified
Journal Article
Open access
PDF file
PRPatricia Ramos-Ramirez
Patricia Ramos-Ramirez
Omar TlibaOmar Tliba
Omar Tliba
Glucocorticoids (GCs) act via the GC receptor (GR), a receptor ubiquitously expressed in the body where it drives a broad spectrum of responses within distinct cell types and tissues, which vary in strength and specificity. The variability of GR-mediated cell responses is further extended by the existence of GR isoforms, such as GRα and GRβ, generated through alternative splicing mechanisms. While GRα is the classic receptor responsible for GC actions, GRβ has been implicated in the impairment of GRα-mediated activities. Interestingly, in contrast to the popular belief that GRβ actions are restricted to its dominant-negative effects on GRα-mediated responses, GRβ has been shown to have intrinsic activities and “directly” regulates a plethora of genes related to inflammatory process, cell communication, migration, and malignancy, each in a GRα-independent manner. Furthermore, GRβ has been associated with increased cell migration, growth, and reduced sensitivity to GC-induced apoptosis. We will summarize the current knowledge of GRβ-mediated responses, with a focus on the GRα-independent/intrinsic effects of GRβ and the associated non-canonical signaling pathways. Where appropriate, potential links to airway inflammatory diseases will be highlighted.

27 May 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
YAYassine Amrani
Yassine Amrani
RPReynold A. Panettieri
Reynold A. Panettieri
PRPatricia Ramos-Ramirez
Patricia Ramos-Ramirez
DSDedmer Schaafsma
Dedmer Schaafsma
KKKlaudia Kaczmarek
Klaudia Kaczmarek
Omar TlibaOmar Tliba
Omar Tliba

22 August 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JZJingbo Zhang
Jingbo Zhang
LKLatifa Koussih
Latifa Koussih
LSLianyu Shan
Lianyu Shan
AHAndrew J Halayko
Andrew J Halayko
Omar TlibaOmar Tliba
Omar Tliba
AGAbdelilah S Gounni
Abdelilah S Gounni
Pentraxin-3 (PTX3) is a multifunctional protein involved in both innate and adaptive immunity. Glucocorticoid (GC) is the first-line therapy to mitigate airway inflammation in asthma. Previous pieces of evidence showed that GC has divergent effects on PTX3 production in various cell types. The molecular mechanisms controlling PTX3 expression in HASMC are, however, not yet characterized. In this study, we demonstrate that the synthetic GC, dexamethasone (DEX) increases the expression of PTX3 both at the protein and mRNA levels. We also found that such an effect of DEX was dependent on de novo protein synthesis and the GC receptor (GR). While DEX increases PTX3 mRNA stability, it did not affect its promoter activity. Interestingly, HASMC pre-treated with p42/p44 ERK inhibitor, but not with p38 or JNK-MAPK inhibitors, significantly interfered with DEX-induced PTX3 secretion. Taken together, our data suggest that GC regulates PTX3 expression in HASMC through transcriptional and post-transcriptional mechanisms in a GR and ERK-dependent manner.

1 July 2019 in Immunobiology
Verified
Journal Article
Closed access
HBHong Bui
Hong Bui
YAYassine Amrani
Yassine Amrani
BDBrian Deeney
Brian Deeney
RPReynold A. Panettieri
Reynold A. Panettieri
Omar TlibaOmar Tliba
Omar Tliba